Meade, Angela M

Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: Results of the randomised phase 3 MRC COIN trial

Maughan, T. S., Adams, R. A., Smith, C. G., Meade, A. M., Seymour, M. T., Wilson, R. H., Idziaszczyk, S., Harris, R., Fisher, D., Kenny, S. L., et al. (2011) · The Lancet

Colorectal Cancer Treatments and StudiesColorectal Cancer Surgical Treatments

Cited by 960

KRAS and BRAF Mutations in Advanced Colorectal Cancer Are Associated With Poor Prognosis but Do Not Preclude Benefit From Oxaliplatin or Irinotecan: Results From the MRC FOCUS Trial

Richman, S. D., Seymour, M. T., Chambers, P., Elliott, F., Daly, C. L., Meade, A. M., Taylor, G., Barrett, J. H., & Quirke, P. (2009) · Journal of Clinical Oncology

Colorectal Cancer Treatments and StudiesColorectal Cancer Surgical Treatments

Cited by 560

Image-based consensus molecular subtype (imCMS) classification of colorectal cancer using deep learning

Sirinukunwattana, K., Domingo, E., Richman, S. D., Redmond, K. L., Blake, A., Verrill, C., Leedham, S. J., Chatzipli, A., Hardy, C., Whalley, C. M., et al. (2021) · Gut

AI in cancer detectionRadiomics and Machine Learning in Medical Imaging

Cited by 264